Urology News and Research RSS Feed - Urology News and Research

Urology is the field of medicine that focuses on the urinary tracts of males and females, and on the reproductive system of males. In men, the urinary system overlaps with the reproductive system, and in women the urinary tract opens into the vulva. In both sexes, the urinary and reproductive tracts are close together, and disorders of one often affect the other. The organs covered by urology include the kidneys, ureters, urinary bladder, urethra, and the male reproductive organs (testes, epididymis, vas deferens, seminal vesicles, prostate and penis).
Further Reading
FTC requests additional information relating to Actavis’ pending acquisition of Forest Laboratories

FTC requests additional information relating to Actavis’ pending acquisition of Forest Laboratories

Actavis plc and Forest Laboratories, Inc. today announced that they have each received a request for additional information from the Federal Trade Commission ("FTC") in connection with Actavis' pending acquisition of Forest. [More]

Actavis to purchase four currently marketed products from Akorn

Actavis plc, a leading global specialty pharmaceutical company, today announced that it has entered into agreements with Akorn, Inc. and Hi-Tech Pharmacal Co. Inc. to purchase four currently marketed products and one product under development [More]

NICE recommends FIRMAGON for treating advanced hormone-dependent prostate cancer in adults with spinal metastases

The National Institute for Health and Care Excellence (NICE) today issued its Final Appraisal Determination (FAD) recommending FIRMAGON (degarelix) as an option for treating advanced hormone-dependent prostate cancer, only in adults with spinal metastases who present with signs or symptoms of spinal cord compression. [More]
Community efforts boost people for HIV testing and reduce new infections

Community efforts boost people for HIV testing and reduce new infections

Communities in Africa and Thailand that worked together on HIV-prevention efforts saw not only a rise in HIV screening but a drop in new infections, according to a new study in the peer-reviewed journal The Lancet Global Health. [More]
Urologists offer new tool for visualizing, monitoring prostate in men with greater accuracy

Urologists offer new tool for visualizing, monitoring prostate in men with greater accuracy

Urologists at Rush University Medical Center are the first in Chicago to offer a powerful new tool for visualizing and monitoring the prostate in men who have high prostate-specific antigen (PSA) levels and in detecting prostate cancer more accurately. [More]

Adjuvant radiotherapy after prostatectomy ‘risks urinary incontinence’

Men who receive adjuvant radiation therapy following radical prostatectomy face a significantly increased risk of urinary incontinence in the following years, study findings indicate. [More]

Prostate cancer breakthroughs offer new hope for men

Men have lower life expectancy than women. This discrepancy is especially pronounced for African American men who live 6 fewer years than women. According to the CDC, life expectancy in the US is 76 years for men compared to 81 for women. [More]

Patient-friendly examination method reduces need for prostate cancer biopsies

Each year prostate tissue samples are taken from over a million men around the world - in most cases using 12 large biopsy needles - to check whether they have prostate cancer. [More]

Bladder outlet obstruction shows distinct urodynamic patterns

Chinese researchers have identified a number of distinct urodynamic patterns among older men with non-neurogenic lower urinary tract symptoms and bladder outlet obstruction. [More]

ICIQ bladder diary ‘psychometrically valid’

UK researchers in collaboration with patients and clinicians have developed a new diary to be used to record lower urinary tract symptoms. [More]
Astellas, Medivation submit European Marketing Authorization Application for XTANDI capsules

Astellas, Medivation submit European Marketing Authorization Application for XTANDI capsules

Astellas Pharma Inc. and Medivation Inc. today announced the submission of a variation to amend the European Marketing Authorization Application for XTANDI® (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated. [More]

Actavis opens new regional headquarters in Singapore

Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced the official opening of its new regional office in Singapore that will serve as the headquarters for the Company's Asia Pacific and Africa (APACA) region. [More]
Actavis announces acquisition of Silom Medical for $100 million

Actavis announces acquisition of Silom Medical for $100 million

Actavis plc, a leading global specialty pharmaceutical company today announced that it has acquired Silom Medical Company, a privately held generic pharmaceutical company focused on developing and marketing therapies in Thailand, for approximately $100 million in cash. [More]

Antimuscarinics plus α-blockers ‘recommended for male LUTS’

Antimuscarinics “could and should” be used in the pharmacological treatment of men with lower urinary tract symptoms caused by benign prostatic hyperplasia or bladder outlet obstruction, say the authors of a meta-analysis published in Urology. [More]

Actavis gets favorable ruling in patent suit against generic Lialda

Actavis plc today confirmed that the United States Court of Appeals for the Federal Circuit has reversed a lower court ruling that Actavis' generic version of Shire's Lialda (mesalamine extended-release tablets) infringes United States Patent No. 6,773,720 (the '720 Patent). [More]
Scientists move a step closer to preserving fertility in young boys with cancer

Scientists move a step closer to preserving fertility in young boys with cancer

Scientists have moved a step closer to being able to preserve fertility in young boys who undergo chemotherapy and radiation treatments for cancer. The new research, published in Fertility and Sterility, the journal of the American Society for Reproductive Medicine, addresses the safety of an option scientists are developing for boys who aren't sexually mature and cannot bank sperm. [More]

PatientPoint signs distribution agreement with HealthTronics IT Solutions for urology technology

PatientPoint announced today that they have entered into a distribution agreement with HealthTronics IT Solutions to deliver population health management solutions within urology to drive improved adherence and compliance. [More]

Prostate stiffness is a risk factor for voiding dysfunction

Prostate elasticity is an independent risk factor for urinary voiding symptoms, although not for lower urinary tract symptoms in general or storage symptoms, clinical research indicates. [More]

Taiho Pharmaceutical obtains approval in Japan for anticancer drug Lonsurf

Taiho Pharmaceutical Co., Ltd. (Tokyo, President: Masayuki Kobayashi) announced on March 24 that it has obtained approval in Japan from the Ministry of Health, Labour and Welfare to manufacture and market the oral combination anticancer drug "Lonsurf(R) combination tablet T15, T20" (nonproprietary names: trifluridine and tipiracil hydrochloride; development code: TAS-102), for the treatment of patients with unresectable advanced or recurrent colorectal cancer (only if refractory to standard therapies). [More]

Renal mass biopsy rates increasing in kidney cancer

Rates of renal mass biopsy have been historically low in patients with kidney cancer, but are steadily rising, shows an analysis of Medicare data. [More]